99mTc-labeled NGR-chlorambucil conjugate, 99mTc-HYNIC-CLB-c(NGR) for targeted chemotherapy and molecular imaging

Journal of Labelled Compounds and Radiopharmaceuticals

Volumn 60, Issue 9, 2017, Pages 431-438

  Vats, Kusum ^a   Satpati, Drishty ^a   Sharma, Rohit ^a   Kumar, Chandan ^a   Sarma, Haladhar D ^a   Dash, Ashutosh ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

99mTc HYNIC; chlorambucil; cytotoxicity; NGR peptide; peptide drug conjugate

Indexed keywords

6 HYDRAZINONICOTINIC ACID CHLORAMBUCIL ASPARAGYLGLYCYLARGININE 99M TC CONJUGATE; ASPARAGYLGLYCYLARGININE; CHLORAMBUCIL; POLYPEPTIDE; TRACER; UNCLASSIFIED DRUG; 6-HYDRAZINOPYRIDINE-3-CARBOXYLIC ACID; ASPARAGINE-GLYCINE-ARGININE; HYDRAZINE DERIVATIVE; NICOTINIC ACID DERIVATIVE; OLIGOPEPTIDE; TECHNETIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B16-F10 CELL LINE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG STABILITY; HEART TISSUE; HUMAN; HUMAN CELL; HYDROPHILICITY; IN VITRO STUDY; INTESTINE TISSUE; ISOTOPE LABELING; KIDNEY TISSUE; LIVER TISSUE; LUNG PARENCHYMA; MELANOMA B16; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; MOUSE; MUSCLE TISSUE; NONHUMAN; PEPTIDE SYNTHESIS; SOLID PHASE SYNTHESIS; SPLEEN TISSUE; STOMACH TISSUE; ANIMAL; CHEMISTRY; DIAGNOSTIC IMAGING; EXPERIMENTAL MELANOMA; TISSUE DISTRIBUTION;

ANIMALS; CHLORAMBUCIL; HYDRAZINES; ISOTOPE LABELING; MELANOMA, EXPERIMENTAL; MICE; MOLECULAR TARGETED THERAPY; NICOTINIC ACIDS; OLIGOPEPTIDES; TECHNETIUM; TISSUE DISTRIBUTION;

EID: 85021254949     PISSN: 03624803     EISSN: 10991344     Source Type: Journal    
DOI: 10.1002/jlcr.3522     Document Type: Article

References (26)

1. Böhme D, Beck-Sickinger AG. Drug delivery and release systems for targeted tumor therapy. J Pept Sci. 2015;21:186-200.
2. Mezo G, Manea M. Receptor-mediated tumor targeting based on peptide hormones. Expert Opin Drug Deliv. 2010;7:79-96.
3. Redko B, Ragozin E, Andreii B, et al. Synthesis, drug release, and biological evaluation of new anticancer drug-bioconjugates containing somatostatin backbone cyclic analog as a targeting moiety. Biopolymers. 2015;104:743-752.
4. Zitzmann S, Ehemann V, Schwab M. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res. 2002;62:5139-5143.
5. Corti A, Curnis F, Arap W, Pasqualini R. The neovasculature homing motif NGR: more than meets the eye. Blood. 2008;112:2628-2635.
6. Laakkonen P, Vuorinen K. Homing peptides as targeted delivery vehicles. Integr Biol. 2010;2:326-337.
7. V integrin ligands improves its antineoplastic activity. Cancer Res. 2004;64:565-571.
8. Curnis F, Sacchi A, Borgna L, et al. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol. 2000;18:1185-1190.
9. Corti A, Curnis F, Rossoni G, et al. Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example. BioDrugs. 2013;27:591-603.
10. Gregorc V, Zucali PA, Santoro A, et al. Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin Oncol. 2010;28:2604-2611.
11. Santoro A, Rimassa L, Sobrero AF, et al. Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy. Eur J Cancer. 2010;46:2746-2752.
12. Gregorc V, Citterio G, Vitali G, et al. Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. Eur J Cancer. 2010;46:198-206.
13. Cullis PM, Green RE, Malone ME. Mechanism and reactivity of chlorambucil and chlorambucil-spermidine conjugate. J Chem Soc Perkin Trans. 1995;2:1503-1511.
14. Millard M, Gallagher JD, Olenyuk BZ, Neamati N. A selective mitochondrial-targeted chlorambucil with remarkable cytotoxicity in breast and pancreatic cancers. J Med Chem. 2013;56:9170-9179.
15. Kohn KW, Hartley JA, Mattes WB. Mechanisms of DNA sequence selective alkylation of guanine-N7 positions by nitrogen mustards. Nucleic Acids Res. 1987;15:10531-10549.
16. Sunters A, Springer CJ, Bagshawe KD, et al. The cytotoxicity, DNA crosslinking ability and DNA sequence selectivity of the aniline mustards melphalan, chlorambucil and 4-[bis(2-chloroethyl)amino] benzoic acid. Biochem Pharmacol. 1992;44:59-64.
17. 99mTc radiopharmaceuticals. Ann Nucl Med. 2002;16:79-93.
18. Banerjee S, Pillai MRA. Ramamoorthy N (2001) evolution of Tc-99m in diagnostic radiopharmaceuticals. Semin Nucl Med. 2001;31:260-277.
19. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev. 1999;99:2235-2268.
20. 1]-minigastrin. Bioconjug Chem. 2004;15:864-871.
21. Greenland WEP, Howland K, Hardy J, et al. Solid-phase synthesis of peptide radiopharmaceuticals using Fmoc-N-ε-(Hynic-Boc)-lysine, a technetium-binding amino acid: application to Tc-99m-labeled salmon calcitonin. J Med Chem. 2003;46:1751-1757.
22. 99mTc]HYNIC-RGD for imaging integrin αvβ3 expression. Nucl Med Biol. 2006;33:945-952.
23. Abrams MJ, Juweid M, tenKate CI, et al. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med. 1990;31:2022-2028.
24. Gilad Y, Noy E, Senderowitz H, et al. Dual-drug RGD conjugates provides enhanced cytotoxicity to melanoma and non-small lung cancer cells. Biopolymers. 2015; Dec 30. https://doi.org/10.1002/bip.22800
25. 99mTc-labeled chlorambucil analog as a tumor targeting agent. Appl Radiat Isotopes. 2009;67:1644-1649.
26. 99mTc-chlorambucil derivative as a potential tumor imaging agent. J Label Compd Radiopharm. 2017;60:116-123.